Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · National Health Investors (NHI)

NHI adds Lilly H. Donohue to board; CEO Mendelsohn re-appointed as director

Neutral Impact 3 of 5 leadership Written later

National Health Investors increased its board size and appointed Lilly H. Donohue as a director effective February 17, 2026, filling the vacant seat. In a related move, CEO D. Eric Mendelsohn resigned and was immediately re-appointed as a director, with his term running to the 2026 annual meeting, which will complete the board's declassification.

Key points

  • Lilly H. Donohue appointed to the board effective February 17, 2026, with an initial term expiring at the 2026 annual meeting; no committee assignments yet
  • Donohue is President and CEO of Everstory Partners and previously served as CEO of Holiday Retirement and on the board of Sonida Senior Living
  • D. Eric Mendelsohn, President and CEO, resigned as a director and was immediately re-appointed, aligning his term with the declassified board structure
  • After the 2026 annual meeting, all board nominees will stand for one-year terms

The filing

CompanyNational Health Investors (NHI)
Form8-K, current report
Filed with the SECFeb 23, 2026, 4:23 PM ET
Accession number0000877860-26-000030

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.